Literature DB >> 31648295

Letter to the Editor.

David Meyronet1,2,3, François Ducray2,3,4.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31648295      PMCID： PMC6827826          DOI： 10.1093/neuonc/noz161

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Authors:  David N Louis; Caterina Giannini; David Capper; Werner Paulus; Dominique Figarella-Branger; M Beatriz Lopes; Tracy T Batchelor; J Gregory Cairncross; Martin van den Bent; Wolfgang Wick; Pieter Wesseling
Journal:  Acta Neuropathol       Date:  2018-03-01       Impact factor: 17.088

2.  High frequency of H3 K27M mutations in adult midline gliomas.

Authors:  Azadeh Ebrahimi; Marco Skardelly; Martin U Schuhmann; Martin Ebinger; David Reuss; Manuela Neumann; Ghazaleh Tabatabai; Patricia Kohlhof-Meinecke; Jens Schittenhelm
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-04       Impact factor: 4.553

3.  FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Authors:  Alberto Picca; Giulia Berzero; Franck Bielle; Mehdi Touat; Julien Savatovsky; Marc Polivka; Elena Trisolini; Sheida Meunier; Yohann Schmitt; Ahmed Idbaih; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Anna Luisa Di Stefano; Marc Sanson
Journal:  Neurology       Date:  2018-05-04       Impact factor: 9.910

4.  Characteristics of H3 K27M-mutant gliomas in adults.

Authors:  David Meyronet; Maud Esteban-Mader; Charlotte Bonnet; Marie-Odile Joly; Emmanuelle Uro-Coste; Alexandra Amiel-Benouaich; Fabien Forest; Cécilia Rousselot-Denis; Fanny Burel-Vandenbos; Véronique Bourg; Jacques Guyotat; Tanguy Fenouil; Anne Jouvet; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

5.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.

Authors:  Dong-Anh Khuong-Quang; Pawel Buczkowicz; Patricia Rakopoulos; Xiao-Yang Liu; Adam M Fontebasso; Eric Bouffet; Ute Bartels; Steffen Albrecht; Jeremy Schwartzentruber; Louis Letourneau; Mathieu Bourgey; Guillaume Bourque; Alexandre Montpetit; Genevieve Bourret; Pierre Lepage; Adam Fleming; Peter Lichter; Marcel Kool; Andreas von Deimling; Dominik Sturm; Andrey Korshunov; Damien Faury; David T Jones; Jacek Majewski; Stefan M Pfister; Nada Jabado; Cynthia Hawkins
Journal:  Acta Neuropathol       Date:  2012-06-03       Impact factor: 17.088

6.  Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.

Authors:  Giselle López; Nancy Ann Oberheim Bush; Mitchel S Berger; Arie Perry; David A Solomon
Journal:  Acta Neuropathol Commun       Date:  2017-05-15       Impact factor: 7.801

7.  Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.

Authors:  Karisa C Schreck; Surabhi Ranjan; Nebojša Skorupan; Chetan Bettegowda; Charles G Eberhart; Heather M Ames; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2019-03-12       Impact factor: 4.130

8.  H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.

Authors:  Bette K Kleinschmidt-DeMasters; Jean M Mulcahy Levy
Journal:  Clin Neuropathol       Date:  2018 Mar/Apr       Impact factor: 1.368
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.